In the absence of a clearly identifiable cause, the prognosis of patients with interstitial lung disease is grim. This study describes our institutional experience in management of patients who are admitted to an ICU with respiratory insufficiency secondary to idiopathic interstitial pneumonia (IIP). This study was performed to obtain Australian data on patients admitted to an ICU with respiratory insufficiency secondary to IIP. This is a retrospective cohort study of patients with IIP who were admitted to the ICU between December 2007 and December 2013 at one of two university-affiliated academic hospitals in Newcastle, New South Wales. Thirty-six patients (69% male) were admitted to the ICU in respiratory insufficiency from IIP. The median age of the cohort was 71 (66 to 77) years. The median APACHE III score was 68 (56 to 97). Sixty-nine percent (25/36) of patients died in hospital. The median ICU and hospital lengths of stay were 6 (2 to 13.5) and 12 (4.8 to 18.3) days respectively. No significant difference was observed between admission characteristics and mortality. Patients admitted to ICU with respiratory failure secondary to IIP are aggressively investigated and treated, but still have a high mortality rate. Accurate predictors of mortality would be useful in offering aggressive treatment to patients who would benefit from it.
Interstitial lung diseases (ILD) are a wide spectrum of respiratory illnesses that affect the lung parenchyma. Often, ILD have no identifiable underlying cause and are known as idiopathic interstitial pneumonias (IIP) 1 . Based on their clinical, radiological and pathological features, IIP can be classified into major, rare and unclassifiable IIP. The major IIP group comprises idiopathic pulmonary fibrosis, idiopathic non-specific interstitial pneumonia, respiratory bronchiolitis-ILD, desquamative interstitial pneumonia, cryptogenic organising pneumonia and acute interstitial pneumonia (AIP) 2 . These conditions are usually progressive and exhibit fibrosis and inflammation of the lung. The usual presenting symptoms are non-specific and hence establishing a diagnosis can be difficult and usually requires a multidisciplinary approach [3] [4] [5] .
Prognosis is mostly poor with median survival rate varying from 2 to 5.8 years, depending the subtype 2,6 . In the advanced stages of illness, patients suffering from IIP will commonly be referred to an ICU when they develop exacerbations and respiratory insufficiency. Once in an ICU, they undergo a battery of tests to assess severity and establish a definitive diagnosis. Having a definitive diagnosis is important because it helps the clinician's direct management, helps prognosticate depending on the type and severity of IIP and is helpful in setting treatment limitations. Obtaining this elusive definitive diagnosis can take days or even weeks 7 .
IIP is not only difficult to diagnose but also to treat, as there is no specific treatment 8 . Patients frequently require different levels of support depending on severity, which can range from supplemental oxygen to invasive mechanical ventilation.
The mortality rate for patients admitted to an ICU with respiratory failure due to IIP is reported as more than 60%, and can be as high as 100% for patients found to have AIP. AIP is an uncommon subtype of IIP for which there is very little data and has a particularly high mortality rate 6, [9] [10] [11] .
There is no available data from Australia about the incidence, demographics, management strategies and outcomes for patients admitted to intensive care with respiratory insufficiency due to IIP, or AIP in particular. This report aims to describe the experience of two centres in Australia in terms of diagnosis, management and outcomes of patients with IIP and AIP as a subgroup.
Materials and methods
This is a retrospective cohort study of consecutive patients who were admitted to John Hunter Hospital ICU and Calvary Mater Newcastle Hospital ICU between December 2007 and December 2013. These are both university-affiliated hospitals in the city of Newcastle, New South Wales. All patients who were admitted due to respiratory failure with no clear identifiable cause were screened. Patients who had history of ILD but were admitted to ICU for non-respiratory reasons, or patients with ILD secondary to a known cause (such as connective tissue disorders, hypersensitivity pneumonitis, infections, drugs, environmental exposures, or toxin-related pneumonitis), or patients whose files could not be accessed electronically through hospital information systems were excluded from the study. Ethics approval was sought from the Hunter New England Human Research Ethics Committee who gave approval after abridged review and waived the requirement for consent. Data was collected from patients' electronic files using a Clinical Information Access Portal system and Digital Medical Records system. The files included discharge summaries, progress notes, radiology reports and pathology reports.
Data was collected on the following variables: admission demographics, age, gender, smoker status at the time of admission, use of home oxygen, Acute Physiology and Chronic Health Evaluation (APACHE) II and III scores 12, 13 , Simplified Acute Physiology Score (SAPS) II 14 , and the ratio of arterial partial pressure of oxygen and fraction of inspired oxygen on admission to ICU. Data was also collected on ICU and hospital length of stay, the diagnosis on ICU admission and discharge, the type and timing of diagnostic exams (imaging, bronchoscopy, histology), treatment received (ventilatory support, antibiotics, immunosuppressants), the time when treatment was initiated, and both ICU and hospital mortality. For the purpose of this study, AIP was diagnosed only if patients had bilateral ground-glass opacities on chest computed tomography scan with an unidentified cause and the presence of diffuse alveolar damage on histological examination 9 .
Data is presented as descriptive statistics with medians, IQRs, and percentages (n).
Results
Overall, 5585 patient files were screened. We found 405 patients who were admitted to the ICU with respiratory failure (as identified by International Classification of Diseases 10th Revision (ICD-10) codes J80, J84.1, J84.8, and J84.9) 15 . Thirty-six patients who had a final diagnosis of IIP were included in the study.
The cohort was made up of 69.4% (25/36) males and had a median age of 70.5 (66 to 77) years. The characteristics of the overall cohort are reported in Table 1 .
On admission to the ICU, 61% (22/36) of patients were given a provisional diagnosis of exacerbation of idiopathic pulmonary fibrosis, 6% (2/36) had a provisional diagnosis The diagnostic interventions performed, how long after admission they were performed, and the most common results of these investigations are reported in Table 2 . No patient underwent any type of lung biopsy, whether transbronchial or open-lung, while in ICU.
Of the cohort, 77% (27/35) received non-invasive ventilatory support for a median duration of 2.5 (1 to 7.75) days and 55% (20/36) received invasive mechanical ventilation for a median duration of 4 (2.75 to 13) days. Thirty-one percent (11/35) of patients had advance care directives, which specified that they did not wish to receive invasive mechanical ventilation. All IIP patients received antibiotics, 79% (23/29) of patients received steroid therapy, and 37% (10/27) of IIP patients had received steroids prior to ICU admission. The data on treatment provided and its timing is reported in Table 3 .
The mortality rate for the cohort was 69% (25/36), with 55% (20/36) of deaths occurring in the ICU, while the remaining 14% (5/36) occurred in hospital after being discharged from the ICU. Of the patients who died, 16% (4/25) were diagnosed with AIP. A more detailed description of the diagnostic evaluation, management and outcomes of the patients diagnosed with AIP can be seen in Table 4 .
Discussion
This report shows that in two hospitals in Australia, IIP was uncommon in ICUs but had a very high mortality rate (69%). This is consistent with previously published data 16 .
Obtaining a timely diagnosis when patients first present is difficult. This is evidenced by how much and how frequently diagnosis changed from ICU admission to discharge. This is no more evident than in the case of AIP, where there were no diagnoses made on ICU admission, but 16% of IIP patients had been diagnosed with it once histological examination was available, albeit post-mortem. Improvements in this area may help in affording patients who suffer from these conditions a better outcome, which might even come in the form of advance care directives and timely end-of-life care.
In this report, we can see that the usual time for obtaining imaging was the same day of ICU admission and only one day after hospital admission. Unfortunately, in some cases the definitive diagnosis does not come from imaging but from tissue examination. Less than a third of patients had bronchoalveolar lavage. This is not surprising since performing a bronchoscopy on a patient receiving non-invasive ventilatory support is very impractical. In this study, no patient underwent transbronchial biopsy. It is difficult to make assumptions from such a small observational study, but we can ask the question of whether the more aggressive, early use of bronchoscopy to obtain tissue diagnosis would have been beneficial in obtaining a confirmatory early diagnosis and helping the treating physicians make management plans. Flexible bronchoscopy has been reported as safe during mechanical ventilation in severely hypoxic patients 17, 18 . In this cohort surgical biopsy was not undertaken at all. This was probably due to the added morbidity of open-lung biopsy and the small chance that it would change management. It is important to acknowledge that this might be centre-specific and that it is likely that other units in Australia resort to transbronchial biopsy and open-lung biopsy more frequently than reported here. This study proves that treatment options are very limited and often unsuccessful. Antibiotics were given to all patients, if they were not already on them, and often as soon as they were admitted to the ICU. Immunomodulation usually came in the way of pulse steroids, most commonly methylprednisolone, less commonly cyclophosphamide, and very rarely azathioprine. Steroids were usually started early into the patients' ICU stays, so we can only ask whether aggressive treatment with high-dose steroids would be beneficial before a patient deteriorates to the point of requiring ICU admission.
Overall, the mortality rate in this report was similar to that reported in the international literature 16 . In regards to AIP, our experience with the four confirmed patients was very similar to diagnosis, treatment and outcomes reported in a case series by Avnon et al 7 , excepting the fact that openlung biopsy was not performed on any of the patients in our study.
Conclusion
IIP is an uncommon presentation to ICUs but is important because of its high mortality rate in the face of aggressive investigation and treatment. In these two Australian centres, having a relatively aggressive diagnostic workup, broadspectrum treatment and high levels of support did little to improve outcomes. We hope that this report will add to the scarce knowledge of these conditions and their management in ICUs. More research is needed to determine whether early tissue diagnosis could help change management decisions.
